Top Innovators in the Market and Recent Development
- Lonza
- Catalent
- Thermo Fisher Scientific / Patheon
- Charles River Laboratories
- WuXi AppTec / WuXi Advanced Therapies
- Fujifilm Diosynth Biotechnologies
- Samsung Biologics
- Novasep
- Oxford Biomedica
- VGXI
- Viralgen / other European AAV specialists and regional specialists
- Peli BioThermal
- Agility Life Sciences / Marken
- AGC Biologics
- CMC Biologics / Avid Bioservices
- Brammer Bio
- Catalent / Paragon
- BioVectra / regional specialty CDMOs
- Analytics / assay providers
- Small/mid specialist CDMOs and academic GMP manufacturers
Market Growth
The global viral vector-based cell & gene therapy CDMO market size is calculated at US$ 142.77 million in 2024, grew to US$ 162 million in 2025, and is projected to reach around US$ 497.7 million by 2034. The market is expanding at a CAGR of 13.44% between 2025 and 2034.
Market Trends
What are the Trends in the Viral Vector-Based Cell & Gene Therapy CDMO Market?
- The investments and funding support the CDMOs to achieve their future growth. For instance, in November 2024, Biologics CDMO Avid Bioservices declared the acquisition by funds that are managed by British healthcare investment firm GHO Capital Partners and Ampersand with $1.1 billion sale.
- The strategic partnerships and investments drive the growth of CDMOs. For instance, in September 2024, Serán Bioscience, a leading CDMO in providing services related to the development, analytical, and manufacturing to biotechnology and pharmaceutical companies, reported $200 million strategic growth transaction and plans for its new commercial facility.
Value Chain Analysis
R&D
The R&D process in the Viral Vector-Based Cell & Gene Therapy CDMO market includes various stages such as preclinical and early process development, late-stage process development, process validation, and cGMP manufacturing.
Key Players: Lonza, Thermo Fisher Scientific (Patheon), Catalent, FUJIFILM Diosynth Biotechnologies, and Charles River Laboratories.
Clinical Trials and Regulatory Approvals
The clinical trials are driven by outsourcing demand and capacity expansion. The regulatory approvals are given by the USFDA, China's National Medical Products Administration (NMPA), and European EMA.
Key Players: Lonza, Catalent, Thermo Fisher Scientific Inc., Charles River Laboratories, AGC Biologics.
Patient Support and Services
These services include logistics, supply chain management, patient education and engagement, financial and regulatory support.
Key Players: Thermo Fisher Scientific Inc., Lonza, Catalent, Charles River Laboratories, Novartis.
Latest Announcements by Industry Leaders
In April 2025, Wolfgang Wienand, Chief Executive Officer of Lonza announced the launch of its new CDMO structure with three business platforms such as integrated biologics, advanced synthesis, and specialized modalities. This innovation brought into practice to enhance customer proximity, strengthen company’s multimodality offering, and provide scalability for future growth.
Recent Developments in the Market
- In November 2024, Samsung Biologics announced the manufacturing deals with Europe-based pharma worth $668 million.
- In October 2024, Thermo Fisher Scientific Inc. introduced expanded biopharma services, capabilities, and innovations at CPHI Milan 2024.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
